Patent details

Basic Information

Publication number:

EP3795181

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP201966579

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT

French Title of Invention:

TRAITEMENT DE LA DMLA À L'AIDE D'UN VARIANT D'AAV2 ET D'AFLIBERCEPT

German Title of Invention:

BEHANDLUNG VON AMD MIT AAV2-VARIANTE MIT AFLIBERCEPT

SPC Number:

Dates

Filing date:

16/06/2017

Grant date:

06/08/2025

EP Publication Date:

24/03/2021

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

06/08/2025

EP B1 Publication Date:

06/08/2025

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

16/06/2037

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

30/07/2025

 

 

Name:

Adverum Biotechnologies, Inc.

Address:

100 Cardinal Way, Redwood City, CA 94063, United States (US)

Inventor

1

Name:

BLUMENKRANZ, Mark

Address:

United States (US)

2

Name:

GASMI, Mehdi

Address:

United States (US)

Priority

Priority Number:

201662351234 P

Priority Date:

16/06/2016

Priority Country:

United States (US)

Classification

IPC classification:

A61K 48/00; A61K 35/761; A61P 27/02; C12N 15/09;

Publication

European Patent Bulletin

Issue number:

202532

Publication date:

06/08/2025

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

30/06/2026

Annual Fee Number:

10

Annual Fee Amount:

131 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages